Suzanne van Dorp

Recurrent oral ulceration after CD19 CAR T-cell therapy defines a delayed mucosal inflammatory phenotype

Joost Scheffers, Lorraine Treurniet-de Haan, Esther Kret, Marjolein van der Poel et autres

Not available.

nl, us (code pays fourni par la source)

Risk of thrombosis and bleeding following CAR T‐cell therapy: Insights from the Dutch “Follow that CAR!” registry

Amica K. Ko, Pim G. N. J. Mutsaers, Lukas Van Kleij, Amária Vledder et autres

Abstract Chimeric antigen receptor (CAR) T‐cell therapy has significantly improved outcomes in patients with relapsed/refractory aggressive large B‐cell lymphoma (R/R LBCL). Although thrombosis and bleeding complications have been increasingly reported, their clinical relevance and risk factors remain unclear, also due to heterogeneity …

nl (code pays fourni par la source)

Decitabine Conditioning Improves Natural Killer Cell Maturation and Limits CD8+ T Cell Terminal Differentiation Post-Allogeneic Stem Cell Transplantation in Acute Myeloid Leukemia Patients

Jesper van Eck van der Sluijs, Diede van Ens, A. M. Grotens, Esther Fernández Merino et autres

• Characterizing the NK and T cell immune landscape in AML patients post-alloSCT • Decitabine (DAC) conditioning improves NK cell maturation post-alloSCT • DAC conditioning limits CD8 + T cell terminal differentiation post-alloSCT • Donor NK/T cells from DAC conditioned patients remained …

nl (code pays fourni par la source)

High risk of bleeding following CAR T-cell therapy: Insights from the dutch “Follow that CAR!” registry

Amica Ko, Pim G. N. J. Mutsaers, Lukas Van Kleij, Frank W.G. Leebeek et autres

Abstract Background: Chimeric antigen receptor (CAR) T-cell therapy has revolutionized treatment and outcomes for patients with relapsed/refractory aggressive large B-cell lymphoma (R/R LBCL). Cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS) and infections are commonly reported CAR T-cell-related toxicities. Recently, …

nl (code pays fourni par la source)

ZUMA-25 preliminary analysis: A Phase 2 study of brexucabtagene autoleucel (brexu-cel) in patients (Pts) with relapsed/refractory (R/R) burkitt lymphoma (BL), substudy C

Suzanne van Dorp, Georg Stüssi, Anna Maria Frustaci, Ian W. Flinn et autres

Abstract Introduction: Brexu-cel is an autologous anti-CD19 CAR T-cell therapy approved for adults with R/R MCL and R/R B-ALL. BL is a rare, highly aggressive B-cell malignancy characterized by translocation of the MYC oncogene. Pts with R/R BL have limited treatment options …

nl, ch, it, us, de, es, at, fr (code pays fourni par la source)

Transformed FL shows improved survival after CAR T-cell therapy compared to de novo LBCL, but early transformation (<12 months) defines a poor-risk subgroup: Results from a nationwide cohort

Hilde Van Der Galien, Pim G. N. J. Mutsaers, Margot Jak, Marjolein van der Poel et autres

Abstract Background Large B-cell lymphoma (LBCL) can arise from transformation of indolent lymphomas, most commonly follicular lymphoma (FL). While only 5-10% of 1st line LBCL cases are transformed FL (tFL), this increases to ~30% in the ≥3rd line CAR T-cell therapy (CART) …

nl (code pays fourni par la source)

Operational burden and fragmented implementation in CAR T‐cell therapy: Insights from a multinational survey by the GoCART Coalition and the JACIE Quality Managers Committee

Nick van Sinderen, Julie Dolva, Caterina Riillo, Raquel Espada et autres

Chimeric-antigen-receptor (CAR) T-cells have rapidly become a cornerstone in the treatment of advanced hematological malignancies, 1 offering transformative outcomes for patients.Since the approval of the first two products in 2017, the number of authorized CAR T-cell therapies has steadily increased, with at …

de, no, nl, fr, it, es, gb, be, dk (code pays fourni par la source)

PLENARY SESSION 2: IMMUNOLOGY AND MICROENVIRONMENT IN MDS

Willemijn A. Hobo, Diede van Ens, Saskia M. C. Langemeijer, Jolanda Brummelman et autres

nl (code pays fourni par la source)

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections, and survival after CART in R/R LBCL

Janneke de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G. N. J. Mutsaers et autres

ABSTRACT: Early identification of patients at risk of immune effector cell-associated hematotoxicity (ICAHT) is essential to minimize nonrelapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections, and survival in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) …

nl (code pays fourni par la source)

Good manufacturing practice production of an off-the-shelf CD34+ progenitor-derived NK cell product with preserved anti-tumor functionality post-infusion in NOD/SCID/IL2Rgnull mice

Laura Hooijmaijers, Marcos Vidal-Manrique, Bart Spils, Diede van Ens et autres

The adoptive transfer of natural killer (NK) cells represents a promising cancer therapy due to their intrinsic ability to distinguish between malignant and healthy cells in an allogeneic context, enabling off-the-shelf manufacturing possibilities. On demand availability of cryopreserved advanced therapy medicinal products …

nl (code pays fourni par la source)

Population-based validation of the CAR-HEMATOTOX for hematotoxicity, infections and survival after CART in R/R LBCL

Janneke de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G. N. J. Mutsaers et autres

Early identification of patients at risk of immune effector cell–associated hematotoxicity (ICAHT) is essential to minimize nonrelapse mortality. The CAR-HEMATOTOX (HT) score is an implemented risk-stratification tool for ICAHT, infections, and survival in patients with relapsed/refractory large B-cell lymphoma (R/R LBCL) receiving …

Population-Based External Validation of the CAR-Hematotox Score to Predict CAR T Cell Related Toxicity and Outcome in R/R LBCL Patients

Janneke de Boer, Kylie Keijzer, Suzanne van Dorp, Pim G. N. J. Mutsaers et autres

Early identification of patients with an increased risk for immune effector cell-associated hematotoxicity (ICAHT) is essential to enable early intervention and thereby minimize non-relapse mortality due to toxicities and infections. Therefore, the CAR-HEMATOTOX (HT) score has been proposed as a risk-stratification tool …

nl (code pays fourni par la source)